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Background: Carbapenems (CAR), colistin (CST), and tigecycline (TGC) alone or in
combination therapy has become the last-resort antibiotics for treating infections caused
by multidrug resistant (MDR) bacteria. However, resistance to these reserve antibiotics
are increasingly being reported worldwide. Hence, the quest to find other agents that will
synergistically restore the efficacy of these antibiotics have increased.
Methods: Sixty-three clinical Enterobacteriaceae isolates comprising of Klebsiella
pneumoniae (n = 24), Enterobacter spp. (n = 15), Serratia marcescens (n = 12),
Citrobacter freundii (n = 8), Escherichia coli (n = 2), and K. oxytoca/michiganensis
(n = 2) with known carbapenem resistance mechanisms and undescribed CST and
TGC resistance mechanisms were subjected to broth microdilution and meropenem
(MEM) disc synergy test in the presence and absence of carbonyl cyanide
m-chlorophenylhydrazine (CCCP), a H+ conductor (protonophore).
Results and conclusions: Susceptibility to MEM, imipenem (IMP), CST, and TGC was
found in only 2, 0, 17, and 9 isolates respectively. Addition of CCCP reversed resistance
to CST, TGC, IMP, and MEM in 44, 3, 0, and 0 isolates respectively; CST had the
highest mean minimum inhibitory concentration (MIC) fold change (193.12; p < 0.0001)
post CCCP compared to that of MEM (1.70), IMP (1.49) and TGC (1.16). Eight isolates
tested positive for the MEM-CCCP disc synergy test. We concluded that CCCP reverse
CST resistance in CST-resistant Enterobacteriaceae. Although CCCP is an experimental
agent with no therapeutic value clinically, further studies are necessary to decipher the
mechanisms underlying the CST-CCCP synergy to inform the development of adjuvants
that could be therapeutically effective in CST-resistant infections.
Keywords: carbapenem, efflux pumps, colistin, CCCP, protonophore, tigecycline
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INTRODUCTION
Bacterial resistance to last-resort antibiotics viz., carbapenems
(CAR), colistin (CST), and tigecycline (TGC), continues to pose a
major clinical challenge to infection treatment and management
throughout the world (Osei Sekyere, 2016; Osei Sekyere et al.,
2016b). Among Gram-negative bacteria, Enterobacteriaceae are
commonly implicated in resistance to carbapenems through
mechanisms such as carbapenemases, porin downregulation,
and/or eﬄux upregulation (Patel and Bonomo, 2013; Sekyere
et al., 2015; Osei Sekyere et al., 2016a). On the other hand,
resistance to CST is mediated by lipid A modifications through
chromosomal mutations (in mgrB, pmrAB, phoPQ, and/or
pmrHFIJFKLM) or the plasmid-borne mcr-1/2 gene (Olaitan
et al., 2014; Osei Sekyere, 2016; Pragasam et al., 2017). TGC
is a glycylcycline that is known to affect protein synthesis by
binding to the ribosomal RNA; however, the major mechanism of
resistance to TGC is hyperexpression of RND-type eﬄux pumps
(Osei Sekyere et al., 2016b). Mutations in regulatory genes (soxS,
ramA, marA, and rarA) leads to up-regulation of AcrAB-TolC
intrinsic RND-type multidrug eﬄux pumps and TGC resistance
(Osei Sekyere et al., 2016b). In addition, acquisition and hyper
expression of oqxAB exogenous RND-typemultidrug eﬄux genes
confers resistance to TGC (Osei Sekyere et al., 2016b; Pournaras
et al., 2016).
Due to the importance of the cell envelope in mediating
resistance to antibiotics through its physicochemical
properties, porin channels, and eﬄux pumps, attention is
being drawn to protonophores such as carbonyl cyanide
m-chlorophenylhydrazine (CCCP), which is used as an
experimental agent with no therapeutic value clinically (Li et al.,
2015), as models to study the interactions between antibiotics
and the cell envelope’s components (plasma membrane, cell wall
and capsule; Spindler et al., 2011; Mohamed et al., 2016; Ni et al.,
2016). Protonophores (e.g., CCCP) reduce ATP production and
increase membrane permeability in bacteria (Spindler et al.,
2011; Park and Ko, 2015; Mohamed et al., 2016; Ni et al., 2016)
by interfering with the transmembrane electrochemical gradient
and proton motive force (Spindler et al., 2011; Yu et al., 2015).
By depolarizing the plasma membrane and reducing ATP
production, protonophores such as CCCP can indirectly affect
the activity of proton pumps and cellular metabolism to cause
cell death (Spindler et al., 2011; Yu et al., 2015). CAR as β-
lactam antibiotics, act on the cell wall by inhibiting peptidoglycan
synthesis to cause cell lysis (Sekyere et al., 2015; Mohamed et al.,
2016). CST is a polymyxin that acts on lipopolysaccharides of the
cell membrane to displace Ca2+ ions and lyse the cell membrane
(Yu et al., 2015; Mohamed et al., 2016; Osei Sekyere et al.,
2016b). Due to the association of the bacterial cell envelope (cell
wall, cell membrane, and capsule) with the resistance of these
important reserve antibiotics, and the ability of protonophores
to influence the permeability and energy of the cell envelope, we
sought to investigate the effect of CCCP on the resistance of these
antibiotics.
CCCP has been reported to reduce eﬄux activity in CAR-
resistant Gram-negative bacteria such that resistance to CAR
was reduced or reversed (Huang et al., 2008). It has also been
shown to effectively reduce or reverse CST resistance in some
Gram-negative bacteria (Park and Ko, 2015; Ni et al., 2016),
and its effect on TGC resistance has been shown to be relatively
lower or insignificant (He et al., 2015). For instance, the study
by Ni et al. (2016) involved only two Klebsiella pneumoniae
species out of all the Gram-negative samples/isolates used in
that study. Hence, these two K. pneumoniae species, of which
only one was colistin-resistant, were the only Enterobacteriaceae
species used. The rest were all Gram-negative non-fermenters
such as Acinetobacter baumannii, Pseudomonas aeruginosa, and
Stenotrophomonas maltophila. The study by Park and Ko (2015)
also involved only A. baumannii and no Enterobacteriaceae.
Therefore, to our knowledge, this is surely the only study
involving a true representation and substantial population of
Enterobacteriaceae.
Moreover, previous studies did not consider the effect of
CCCP on CAR, CST, and TGC simultaneously or in tandem
(Park and Ko, 2015; Mohamed et al., 2016; Ni et al., 2016). This
study attempts to analyse the interaction between CCCP and
CAR, CST, and TGC in reversing IMP, MEM, CST, and TGC
resistance from a CCCP-antibiotic synergy perspective with the
hope that future studies will investigate potential ionophores that
can serve as adjuvants to restore the potency of these reserve
antibiotics.
MATERIALS AND METHODS
Ethical Approval
The Biomedical Research Ethics Committee of the University of
KwaZulu-Natal Ethical approved this study under the reference
number BE040/14.
Bacterial Strains
A collection of 63 clinical isolates of multiple lineages comprising
of K. pneumoniae (n= 24), Enterobacter species (n= 15), Serratia
marcescens (n = 12), Citrobacter freundii (n = 8), Klebsiella
oxytoca (n = 2), and Escherichia coli (n = 2) with well-described
carbapenem resistance mechanisms (mainly blaNDM−1 and
blaGES−5) and unknown CST and TGC resistance mechanisms
were used (Table 1); known and well-described CST (mcr-
1/2, mutations and insertional inactivation of mgrB, pmrAB,
phoPQ, and pmrHFIJFKLM) and TGC (mutations in acrAB,
rarA, ramAR, marABR, and soxS) resistance mechanisms were
not found in 48 isolates when their genomes were compared to
that of wild type strains (TGC-susceptible strains of each specie):
K. pneumoniae MGH78578 (accession number CP000647);
E. cloacae NCTC 9394 (accession number FP929040.1); E. coli
ATCC 25922 (accession number CP009072); S. marcescens
ATCC 13880 (accession number KN050642.1). The isolates were
obtained from a private pathology laboratory in Durban, South
Africa. The isolates were sourced from 10 private hospitals in
Durban by the private pathology laboratory.
Forty-eight of the isolates had been previously characterized
using whole genome sequencing (WGS; bioproject number
PRJNA287968) to characterize their resistome, and 12 had been
characterized by PCR (Osei Sekyere et al., 2016a) to identify
their carbapenem resistance mechanisms; three isolates had been
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subjected to the Carba NP test (Table 1; Osei Sekyere et al.,
2016a,c) to determine if they were carbapenemase producers.
CST and TGC resistance mechanisms could not be investigated
in 15 isolates that had not been subjected to whole genome
sequencing (WGS; Table 1). Five out of the 63 isolates (60,
45_S21, 1_S1, 65_S32, and 14_S7) were non-carbapenemase-
producing whilst K. pneumoniae ATCC BAA 1706 (KP 1076)
and E. coli ATCC 25922, which were susceptible to all the
antibiotics, were used as controls (Pragasam et al., 2016;
Table 1).
Antibiotics, CCCP, VRP, and RSP
Antibiotics, namely MEM, IMP, CST, TGC, and CCCP, which is
used herein as an experimental protonophore; as well as eﬄux
pump inhibitors (EPIs) viz., verapamil (VRP) and reserpine
(RSP) in powder form were purchased from Sigma-Aldrich (St
Louis, USA). VRP is a calcium (Ca2+) channel blocker and
RSP is a plant-derived eﬄux pump inhibitor that block MATE,
SMR, and ABC-type eﬄux pumps, particularly in Gram-positive
bacteria and in mycobacteria (by VRP); their use in Gram-
negative bacteria is so far minimal although eﬄux inhibition has
been reported (Li et al., 2015; Radchenko et al., 2015; Pule et al.,
2016). Solutions of VRP were prepared in deionized water whilst
RSP was prepared in dimethyl sulfoxide (DMSO) and CCCP in
50% methanol (v/v) (Pragasam et al., 2016). All solutions were
prepared on the day of the experiment and kept protected from
the light.
MICs Determinations of CCCP, RSP, VRP,
MEM, IMP, CST, and TGC
The broth microdilution method was used for the determination
of MICs using the Cation-adjusted Mueller-Hinton broth
(Sigma-Aldrich, St Louis, USA). The MICs of CCCP, RSP,
and VRP were determined using a randomly selected number
(n = 27) of isolates and controls (Supplementary Table S1). A
sub-MIC of these compounds at final concentrations of 10, 256,
and 256 mg/L for CCCP, RSP, and VRP respectively were used in
determining their effects onMEM, IMP, CST, and TGC resistance
to reduce the possibility of their toxicity being responsible for
the change in MEM, IMP, CST, and TGCMIC; the concentration
of the inhibitors were constantly kept at the MIC concentrations
stated above whilst that of the antibiotics were serially increased
(Supplementary Table S1). A sub-MIC of 5 mg/L was used for
isolate 29_S13, which had a CCCP MIC of 8 mg/L.
The MICs of the isolates to MEM, IMP, CST, and TGC in
the absence and presence of CCCP was determined using a
sub-MIC of CCCP (final concentration of 10 mg/L) as already
described (Park and Ko, 2015; He et al., 2015). The concentration
of antibiotics used per well was increased serially by two-fold
whilst that of CCCP was kept constant. EUCAST breakpoints
(2016) were used to interpret the results (European Committee
on Antimicrobial Susceptibility Testing, 2016).
MEM-CCCP Disc Synergy Test
Antimicrobial sensitivity testing (AST) using the disc diffusion
method with MEM discs (MAST Group, Merseyside, UK) was
undertaken as already described for all the 63 isolates (Clinical
Laboratory Standards Institute (CLSI), 2009). Two MEM discs
were used per plate and 10 µL of 20 mg/L CCCP (Sigma Aldrich,
St. Louis, MO, USA) was dispensed on one MEM disc per plate
prior to incubation at 37◦C for 24 h. A difference of ≥5mm in
zone diameter between MEM discs alone and MEM with CCCP
was taken as positive for eﬄux pump-mediated carbapenem
resistance (Table 1; Huang et al., 2008).
Data and Statistical Analysis
The MIC fold changes resulting after the addition of CCCP, RSP,
and VRP were calculated as the ratio of theMICs of the antibiotic
alone to that of the antibiotic plus CCCP. A fold change of
≥8 was adopted as significant. The mean MIC fold change per
antibiotic per specie was calculated with the following equation:
1/total sample size (n)× sum
(
MIC fold change
× frequency of fold change
)
.
Where the “frequency of fold change” is the number of times a
particular MIC fold change was recorded for that antibiotic and
specie. Fold changes of >1, ≥2, >8 were used as 1, 2, and 8,
respectively, in the mean fold change analysis. The mean fold
change per species was translated into a graph using Microsoft
ExcelTM 2016 (Figure 1).
Results were expressed as mean MIC fold changes of
antibiotics per enterobacterial specie upon addition of CCCP
(Table 1 and Supplementary Tables S1–S3). The statistical
analyses were carried out using non-parametric one-way
analysis of variance (ANOVA) followed by Dunnett’s multiple
comparison test. Fold changes with a P < 0.05 were considered
statistically significant: ∗P < 0.05, ∗∗P < 0.01 and ∗∗∗P <
0.001. All analyses were performed with GraphPad Prism 5.0 for
Windows (GraphPad Software, San Diego, CA, USA).
RESULTS
RSP and VRP Have No Effect on IMP, MEM,
CST and TGC Resistance
The MICs of CCCP, RSP, and VRP in the various species ranged
from 8 to 64, 512 to >512, and 512 to >512 mg/L, respectively
(Supplementary Table S1). The concentration of CCCP used
(10m g/L) was well below its MIC except for one isolate that
had an MIC of 8 mg/L for which 5 mg/L CCCP was used; hence,
CCCP toxicity on the bacterial cells used in this study is minimal
or null. Addition of sub-MICs of RSP and VRP to the antibiotics
resulted in no change in the antibiotics’ MICs (Supplementary
Table S1; fold change = 1). Moreover, the influence of MFS,
ABC, and SMR eﬄux pumps that are not inhibited by RSP and
VRP in Gram-negative bacteria on these isolates’ MICs cannot
be excluded: MATE-type and RND types of eﬄux pumps are
believed to be affected by VRP and RSP respectively (Ribera et al.,
2002; Shinabarger et al., 2011; Surendranath et al., 2014; Li et al.,
2015; Radchenko et al., 2015).
Per the MICs of CCCP, RSP, and VRP alone as well as that
of RSP and VRP plus IMP, MEM, CST, and TGC shown in
Supplementary Table S1, there were no changes in the MIC of
the antibiotics upon addition of the inhibitors. The fold change
was one for all species and antibiotics. Due to the mechanism of
resistance RSP and VRP as actual EPIs, the role of eﬄux pumps
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FIGURE 1 | A graphical view of the mean MIC of MEM, IMP, CST, and TGC fold changes after the addition of CCCP. The addition of CCCP to the bacterial
culture medium either changed or did not change the MIC of MEM, IMP, CST, or TGC to the respective enterobacterial isolates (K. pneumoniae, S. marcescens,
Enterobacter spp., Citrobacter freundii, E. coli, and K. oxytoca/michiganensis). The greatest MIC changes occurred in CST with substantial statistical significance
(p-value was 0.0001> × <0.0099) among all the isolates whilst a statistically insignificant change was observed with all the other antibiotics.
in conferring resistance to the antibiotics and the probability of
CCCP affecting the antibiotics’ MICS indirectly through eﬄux
pumps was ascertained.
CCCP Interacts with CST, but Not with
CAR and TGC
CCCP reversed resistance to CST in 44 isolates and reduced
CST MIC by several (from 2 to 1024) folds in almost all the
isolates, with a mean fold change of 193.12; 49 isolates had a
CST MIC fold change between 64 and 512 and three had no
change at all. CST p-values ranged from < 0.0099 to <0.0001 in
the various species; see Supplementary Table S3. CCCP reversed
resistance to TGC in only three isolates, and the overall mean
fold change in TGC MICs was 1.16. CCCP could not reverse
resistance to MEM and IMP, and their average MIC fold changes
were 1.70 and 1.49, respectively. The mean MIC fold change per
species is shown in Figure 1 and the p-values for CST mean
fold change per species are shown in Supplementary Table S3;
that of IMP, MEM and TGC are not shown as they were far
below the≥eight-fold change cut off and also had insignificant p-
values. Susceptibility to TGC, CST,MEM, and IMP in the absence
of CCCP was respectively observed in 17, nine, two and zero
isolates.
Table 1 summarizes the MICs of MEM, IMP, CST, and
TGC alone as well as with CCCP, the carbapenem resistance
mechanism of the isolates and the results of theMEM-CCCP disc
synergy test. The high level of resistance to MEM (with MICs
between 2 and 512 mg/L), IMP (with MICs between 16 and 512
mg/L) and CST (with MICs between 0.5 and 512 mg/L) for all
isolates is easily seen from Table 1.
Four Out of Five MEM-CCCP Positive
Isolates Had a Two-Fold MIC Reduction in
MEM
Only eight isolates (E, H, L, 18_S10, 26, 36_S18, 49_S24, and 60)
tested positive for the CCCP-MEM disc synergy test (Table 1)
and all but two (36_S18 and H) of these had a two-fold reduction
in MEM MIC upon addition of CCCP. Isolate 60 was the only
CAR-resistant isolate that both produced no carbapenemase and
tested positive for the MEM-CCCP test.
CCCP Had No Effect on the MEM and IMP
MICs of Non-carbapenemase-producing
Isolates
Four of the five CAR-resistant but non-carbapenemase positive
isolates (1_S1, 14_S7, 45_S21, 60, and 65_S32) had no change in
IMP and MEMMICs; only isolate 60 had an MIC fold change of
2 upon CCCP addition.
DISCUSSION
Increasing resistance to antibiotics of last-resort is making the
research for novel antibiotics as well as for adjuvants that will
potentiate the effect of existing ones a present necessity (Osei
Sekyere, 2016). Important antibiotics such as β-lactams (e.g.,
CAR) and CST are known to respectively act on the bacterial
cell wall and cell membrane to cause cell lysis and death (Sekyere
et al., 2015; Mohamed et al., 2016; Osei Sekyere et al., 2016b).
Moreover, RND-typemultidrug eﬄux pumpAcrAB-TolC, which
is a major contributor to intrinsic multidrug resistance in
Enterobacteriaceae, is driven by the proton motive force and is
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found in the cell membrane (Ricci et al., 2014; Li et al., 2015;
He et al., 2015). These suggest the important role of the cell wall
and cell membrane (with embedded eﬄux pumps) as potential
drug targets and as a bacterial defense mechanism against
antibiotics. Due to the activity of CCCP as a protonophore that
reversibly binds protons (H+) and transports them across the cell
membrane, leading to membrane depolarization, eradication of
the electrochemical concentration gradient (ECG) and reduced
ATP production by ATP synthase (Spindler et al., 2011; Yu et al.,
2015; Ni et al., 2016), it was used as an experimental model
to investigate how protonophores’ effect on the cell membrane
could affect the potency of themost important reserve antibiotics:
CAR, CST, and TGC.
This study has shown a potential synergy between CCCP
and CST in reversing CST resistance among multidrug resistant
(MDR) Enterobacteriaceae, which can be explored further to
find adjuvants that can restore the efficacy of CST in treating
CST-resistant infections. Mohamed et al. (2016) recently showed
that CST disrupted both the cell membrane and cell wall to
cause cell lysis and death, and that the effect of CST on the
cell wall is similar to that of β-lactams. Ni et al. (2016) argued
that CCCP’s depolarization of the cell membrane might restore
the negative charges, which are neutralized or reduced in CST-
resistant isolates, thus making the resistant cells susceptible to
CST again. On the other hand, Park and Ko (2015) proposed
that the reduction in ATP production, and subsequently a
reduced metabolic activity after treating cells with CCCP, could
be responsible for the enhanced activity of CST as no change was
observed in the expression levels of adeABC and adeIJK eﬄux
genes in both resistant and susceptible isolates.
Using the natural producer of CST, Paenibacillus polymyxa,
Yu et al. (2015) showed that the addition of Ca2+, and to a
lesser extend Mg2+, reduced the bactericidal effect of CST. They
thus showed that Ca2+ and/or Mg2+ depletion was important in
enhancing CST activity. Putting these findings together with our
own, we hypothesize that CCCP depolarization of the membrane
potential and reduction of ATP levels leads to a depletion of or
imbalance in Ca2+ and/or Mg2+ levels in CST-resistant isolates,
which facilitates the easier binding of CST to the lipid A to
cause cell lysis and death. However, this hypothesis would need
to be verified experimentally. The limited role of eﬄux pumps
in conferring CST resistance has also been observed by other
researchers (Park and Ko, 2015; Ni et al., 2016). This is not
surprising given that CST mainly acts on the lipid A of the outer
lipopolysaccharide membrane (Sekyere et al., 2015).
RSP and VRP could not reverse or reduce IMP, MEM, and
TGCMICs (Table 1), providing evidence that they aremost likely
not involved in conferring resistance to IMP, MEM, CST, and
TGC (Osei Sekyere et al., 2016b). Notably, the inability of CCCP
as well as phenylalanine-arginine β-naphthylamide (PaβN), RSP,
and VRP to reverse TGC have been reported, corroborating our
findings (Park and Ko, 2015). Thus, the two-fold reduction in
TGC MIC by CCCP in 10 isolates as well as the reversal of TGC
resistance in three isolates (Table 1) would need further studies
to ascertain the mechanism behind this observation.
The possibility that carbapenemases might overshadow the
effect of increased eﬄux pumps activity in the isolates is most
likely minimal as RSP and VRP had no effect on the isolates’ CAR
resistance. Moreover, among the non-carbapenemase producing
but CAR-resistant isolates, there was no change in CAR MIC
after adding CCCP except in only isolate 60. We hypothesize
that the depolarization of the plasma membrane, the subsequent
cytoplasmic ion imbalance and reduction of ATP production by
CCCPmight affect the optimal activity of carbapenemases, which
require energy and zinc (in the case of NDM-1) to function
(Osei Sekyere et al., 2015) further studies will be necessary to
substantiate this.
CCCP enlarged the inhibition zones around the MEM disc
on the CCCP-MEM disc synergy test to various sizes (data not
shown), albeit a cut-off of ≥5 mm was adopted as positive
according to literature (Huang et al., 2008). A pattern of
two-fold MIC reduction in MEM after adding CCCP was
observed in all but two isolates that tested positive for the
MEM-CCCP. Thus, experimental CCCP does have some effect
on carbapenem (MEM) resistance that could be investigated
further.
Although the peptidomimetic eﬄux-pump inhibitor, PaβN, is
commonly used in Gram-negative bacteria, its effect on CST in
Enterobacteriaceae has been found to be insignificant (Opperman
and Nguyen, 2015; Park and Ko, 2015).
We thus concluded that CCCP reverses CST resistance
in CST-resistant Enterobacteriaceae. Although CCCP is an
experimental agent with no therapeutic value clinically,
further studies are necessary to decipher the mechanisms
underlying the CST-CCCP synergy to inform the development of
adjuvants that could be therapeutically effective in CST-resistant
infections.
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